http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2481334-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e35bbf97602247a396c6cfb8f5d5c5a3 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
filingDate | 2003-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64dac0fe105a10858c53931dc9392c7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81ab30bc299e9c754ba038451e6efc91 |
publicationDate | 2003-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2481334-A1 |
titleOfInvention | Tissue-specific endothelial membrane proteins |
abstract | Methods and compositions for targeting of pharmaceuticals or other therapeutics to specific tissues using tissue-specific endothelial membrane proteins are provided. The compositions comprise a therapeutic complex composed of a ligand, a linker, and a therapeutic moiety, where the therapeutic moiety can enter the cell. The ligand can be an antibody or other molecule that binds to a tissue-specific protein on the endothelial membrane of a specific tissue. The ligand does not activate a receptor, but may activate endocytosis. The therapeutic moiety could be a drug, gene, antisense oligonucleotide, contrast agent, protein, toxin, or any type of molecule that acts on the specific tissue. The linker is preferably cleaved upon going to the interior of the cell. Alternatively, the linker may simply be the bond between the ligand and the therapeutic moiety. Alternatively, a lipophilic prodrug may be cleaved and may enter the cell due to its lipophilic properties. |
priorityDate | 2002-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 3043.